Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2016 07:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe’s Horizon 2020 Program

The study will enroll about 250 patients in Europe and the U.S.The grant will cover a significant portion of the study expenses PLX-PAD was previously selected by the EMA to be developed via the...
August 02, 2016 07:30 ET | Source: Pluristem Therapeutics Inc.

Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

CLI is a severe unmet medical need whose treatment addresses a $12 billion global marketMultinational study to be conducted in U.S. and Europe Estimated trial enrollment of approximately 250...
July 27, 2016 07:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture

Clinical Advisory Board of leading orthopedic specialists and experts in rehabilitation met to discuss the design of the Phase III study prior to submission of the protocol to the FDAPluristem has...
July 20, 2016 07:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID

HAIFA, Israel, July 20, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced its...
July 11, 2016 07:30 ET | Source: Pluristem Therapeutics Inc.

Pluristem Advances its U.S. FDA Trial in Hematologic Indication

Enters into an agreement with a global drug development services company (CRO)Trial was cleared by U.S. FDA earlier this yearData could support use of Pluristem’s PLX-R18 in a broad range hematologic...
June 22, 2016 03:00 ET | Source: Pluristem Therapeutics Inc.

Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy

PLX-PAD cells increase regeneration of muscle tissue and reduce inflammation and cell deathPluristem donated cells for the studies performed in conjunction with ADI- the Association Duchenne Israel ...
May 16, 2016 03:00 ET | Source: Pluri Inc.

Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial

Trial expands to randomize 20 more patients to receive two injections per patientData release on track for 2017HAIFA, Israel, May 16, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
May 10, 2016 03:00 ET | Source: Pluri Inc.

Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

HAIFA, Israel, May 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial...
May 09, 2016 05:00 ET | Source: Pluri Inc.

Pluristem Awarded $3.3 Million Grant by Israeli Government

HAIFA, Israel, May 09, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its wholly...
April 21, 2016 04:00 ET | Source: Pluri Inc.

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

HAIFA, Israel, April 21, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has...